Hematology
Blood Disorders — Didactic Med
Blood Disorders Decoded
Open toolClinicLens specialt
Hematology
28 items automatically indexed in this specialt.
← Back to all specialtiesHematology
Hematology Unveiled - Didactic Med
🩸 Hematology Unveiled
Open toolHematology
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy | ClinicLens
New England Journal of Medicine, Volume 395, Issue 5, Page 440-453, July 30, 2026.
Open articleHematology
Platelet-Activating Anti–Platelet Factor 4 Disorders | ClinicLens
New England Journal of Medicine, Volume 395, Issue 5, Page 478-491, July 30, 2026.
Open articleHematology
Redefining Early Relapse in Multiple Myeloma — Time to Change the Rules | ClinicLens
New England Journal of Medicine, Volume 395, Issue 5, Page 506-507, July 30, 2026.
Open articleHematology
[Editorial] Learning from a decade of progress in amyloidosis | ClinicLens
Improving outcomes for people with rare diseases is a major challenge, but it is possible. Amyloidosis is a heterogeneous group of rare disorders in which amyloid (misfolded protein deposits) accumulates in the tissues, causing progressive organ failure. Until recently, it was a
Open articleHematology
[Comment] Beyond MURANO: sequencing therapy in relapsed chronic lymphocytic leukaemia | ClinicLens
The treatment landscape of chronic lymphocytic leukaemia has undergone a revolution in the past decade. Highly effective targeted therapies have shifted the treatment paradigm from continuous disease control towards fixed-duration combination approaches capable of inducing deep a
Open articleHematology
[Articles] Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated chronic lymphocytic leukaemia
In patients with previously treated chronic lymphocytic leukaemia, PVR showed significant improvement in progression-free survival compared with VR, with consistent results in patients who had previously received covalent BTK inhibitors and no new safety signals. To our knowledge
Open articleHematology
[Review] Systemic light chain and transthyretin amyloidosis—treatment advancements and future directions | ClinicLens
Once rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly treatable. Basic scientific discoveries regarding the molecular mechanisms of transthyretin misfolding and aggregation have driven the development of drugs
Open articleHematology
A distinct CAR-T cell phenotype mediates therapeutic response at limited doses. | ClinicLens
Chimeric antigen receptor (CAR) T-cell therapies are typically administered at high doses to maximize durable clinical responses. However, manufacturing constraints can limit the production of sufficient cells to achieve the intended dose. Although some patients experience durabl
Open articleHematology
Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised,
Acute graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after haploidentical haematopoietic stem-cell transplantation (HSCT). Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor with established activity in steroid-refractory GVHD, has shown promise fo
Open articleHematology
Efficacy and safety of prebiotics, probiotics, and synbiotics on hemoglobin and anemia in the pediatric population: A systematic review and meta-analysis. | Cli
To evaluate the efficacy and safety of prebiotics, probiotics, and synbiotics on hemoglobin levels and anemia in the pediatric population. We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs). PubMed, Embase, and CENTRAL were searched up to Augu
Open articleHematology
Intermittent exogenous ketosis increases erythropoietin in healthy adults: A randomized, placebo-controlled study with preliminary sex-specific observations. |
Exogenous ketosis may stimulate erythropoietin (EPO), yet its impact on erythropoiesis, iron metabolism, and potential sex-specific responses in humans remains unknown. We investigated these effects in healthy adults using oral β-hydroxybutyrate ketone monoester (KE) to induce in
Open articleHematology
Impact of cryopreservation on PBMC-derived CAR-T cell manufacturing outcomes: a systematic review. | ClinicLens
Chimeric antigen receptor T-cell (CAR-T) therapy is an established treatment for several hematological malignancies, with peripheral blood mononuclear cells (PBMCs) serving as the starting material for manufacturing. Cryopreservation of PBMCs may offer logistical flexibility, alt
Open articleHematology
Excess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta
The authors performed a systematic review and meta-analysis to estimate the prevalence of comorbidities among patients with myelodysplastic syndrome (MDS) by pooling results from 28 studies and 71,400 patients. In conducting this research, the authors observed that individuals wi
Open articleHematology
Efficacy and safety of mitoxantrone hydrochloride liposome/ thiotepa/ busulfan/fludarabine (MTBF) conditioning regimen for salvage allogeneic hematopoietic stem
To investigate the efficacy and safety of MTBF as conditioning regimen for salvage allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapsed or refractory acute myeloid leukemia (R/R AML). We conducted a single-arm prospective clinical trial (NCT063
Open articleHematology
Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial. | ClinicLens
Orelabrutinib is a potent, irreversible, and highly-selective BTK inhibitor that has been approved for the treatment of relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL). This randomized, phase 3 study (ClinicalTrials.gov identifier: NCT045786
Open articleHematology
Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma. | ClinicLens
Naturally occurring tumor-specific T cells derived from peripheral blood (PB) offer a clinically accessible source for adoptive immunotherapy. However, the expansion of these T cells from patients with cancer remains a challenge. We hypothesized that mimicking innate immune activ
Open articleHematology
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX
Assessments of chimeric antigen receptor (CAR) T-cell pharmacokinetics by flow cytometry (FC) and a droplet digital PCR (ddPCR) assay were compared in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) following treatment with obecabtagene a
Open articleHematology
Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1
Autologous chimeric antigen receptor (CAR)-T cell therapy is effective in relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), but its clinical application is restricted by manufacturing failures, high costs, and limited accessibility. Gene-edited allogeneic CA
Open articleHematology
Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia. | ClinicLens
Acute myeloid leukemia (AML) is a rapidly progressive malignancy with poor prognosis. To date, chimeric antigen receptor (CAR) T-cell therapy in AML has been limited by the lack of antigens with high specificity for AML cells. Here, we developed a synthetic T-cell receptor and an
Open articleHematology
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. | ClinicLens
Traditional manufacturing of B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapies is prolonged, leading to reduced patient access, T cell exhaustion, and consequently limiting therapeutic efficacy. To address this issue, we developed durcabta
Open articleHematology
Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplas
The optimal regimens for older adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain uncertain. The authors conducted a multicenter phase 2 trial to evaluate the novel venetoclax, fl
Open articleHematology
Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory a
Total marrow and lymphoid irradiation delivers augmented doses of radiation to the bone marrow and lymph nodes while maintaining low doses to vital organs. We aimed to assess the effectiveness of combining total marrow and lymphoid irradiation (2000 cGy to bone marrow and lymph n
Open articleHematology
Biological clocks and blood clots in space: circadian disruption-induced modulation of thrombosis risk. | ClinicLens
Long-duration space missions expose astronauts to microgravity, radiation, confinement, fluid redistribution, and circadian disruption, which together induce physiological adaptations, including cardiovascular hemodynamics. Emerging evidence suggests that spaceflight may modulate
Open articleHematology
Diagnostic accuracy of automated hematology analyzer abnormal flags for detecting hematological malignancies: A systematic review and meta-analysis. | ClinicLen
Hematological malignancies including leukemia, lymphoma, and myelodysplastic syndromes, are characterized by clonal proliferation of abnormal blood or bone marrow cells. Early and accurate detection is essential for improving treatment outcomes and survival. Automated hematology
Open articleHematology
All-Trans Retinoic Acid plus Eltrombopag for Refractory/Relapsed Immune Thrombocytopenia. | ClinicLens
Eltrombopag is an effective second-line therapy for immune thrombocytopenia (ITP), but its long-term efficacy is limited. All-trans retinoic acid (ATRA) has immunomodulatory effects targeting ITP pathophysiology. We investigated whether combining ATRA with eltrombopag improves lo
Open articleHematology
All-Trans Retinoic Acid for Immune Thrombocytopenia - Sustained Response? | ClinicLens
All-Trans Retinoic Acid for Immune Thrombocytopenia - Sustained Response?
Open article